SOUTH SAN FRANCISCO, Calif., Sept. 18, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on September 15, 2025 it granted stock options to purchase an aggregate of 39,790 shares of common stock and 26,822 restricted stock units (RSUs) that will be settled in shares of common stock upon vesting to 11 employees, whose employment commenced in August and September 2025 as a material inducement to their employment.
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Seeking Alpha / 2 hours from now 1 Views
Comments